What are the risks of using Cologuard?
Cologuard, a multi-target stool DNA screening test for colorectal cancer, carries specific clinical and diagnostic risks that patients must understand. A significant concern is the rate of false-positive results, where the test detects abnormal DNA or blood markers despite the patient not having cancer or advanced precancerous polyps, which causes unnecessary anxiety and mandates follow-up diagnostic colonoscopies that carry their own procedural risks. Conversely, the test also carries a false-negative risk, failing to detect existing polyps or cancers and potentially providing a false sense of security that delays proper preventative care. Cologuard is not intended to replace standard screening colonoscopy for high-risk individuals with family histories of colon cancer or inflammatory bowel disease. Additionally, insurance coverage limitations can sometimes leave patients facing unexpected out-of-pocket laboratory expenses if specific policy requirements are not fully satisfied prior to testing.
Related FAQs
Abbott Laboratories holds an elite and legendary status in the financial world regarding shareholder returns, having achieved Dividend King status by increasing its payout for over 50 consecutive years.
Legal actions involving Exact Sciences Corporation, the manufacturer of the Cologuard colon cancer screening test, have included whistleblower and federal False Claims Act lawsuits, as well as employment discrimination claims.
Yes, documents signed through Docusign are legally valid and hold up in court in the vast majority of jurisdictions, including those following United States federal laws like the ESIGN Act and the UETA.
A classic example of an exact science is mathematics or classical theoretical physics, which rely on rigorous deductive reasoning, quantitative measurement, mathematical modeling, and universal physical laws that yield precise, reproducible, and veri...
Scientific inquiry spans diverse disciplines that systematically study the physical and natural world through observation, experimentation, and empirical evidence.
A false negative result with the Cologuard non-invasive stool DNA test occurs when the screening returns a negative outcome even though a patient actually harbors colorectal cancer or significant precancerous advanced adenomatous polyps.
Exact Sciences is generally viewed as a fast-growing, innovative company in the molecular diagnostics industry.
Exact Sciences Corporation (EXAS) operates as a leading molecular diagnostics pioneer renowned for non-invasive cancer screening tests like Cologuard and precision oncology tools like Oncotype DX.
The future performance of Exact Sciences Corporation stock depends heavily on the commercial adoption rates of its flagship non-invasive colorectal cancer screening tests, precision oncology pipeline developments, and quarterly revenue growth.
Coloplast A/S—a major global medical technology enterprise specializing in ostomy care, continence, urology, and wound care products—is publicly traded on global exchanges, meaning retail investors acquire shares based on real-time market valuations ...
Yes, Exact Sciences Corporation was acquired by Abbott Laboratories in a transaction that closed in March 2026.
Mathematics is universally classified as an abstract formal science rather than an empirical natural science, relying on rigorous logical deduction from foundational axioms and definitions.
Exact sciences, also frequently referred to as exact sciences or hard sciences, are fields of study characterized by rigorous quantitative methods, precise mathematical expressions, reproducible experimental procedures, and highly reliable predictive...
In biological classification and zoological terms, a caterpillar is definitively not a cat; rather, it is the immature, larval stage of an insect belonging to the order Lepidoptera, which encompasses butterflies and moths.
Academic and empirical inquiry is broadly categorized into foundational scientific disciplines that systematically investigate the natural, physical, and social universe through rigorous observation and experimentation.
Yes, the acquisition of Exact Sciences (EXAS) by Abbott Laboratories has already been completed. The merger was finalized in March 2026, and Exact Sciences now operates as a direct, wholly owned subsidiary of Abbott.
Prior to its acquisition by Abbott Laboratories, Exact Sciences had been operating with negative net income, though analysts had projected it could turn profitable around the time the merger closed.
Scientific inquiry is broadly categorized into distinct branches that systematically study the natural and physical universe through observation and experimentation.
Exact Sciences Corporation is a prominent American molecular diagnostics and advanced biotechnology company based in Madison, Wisconsin, specializing in the detection and prevention of early-stage cancers.
Exact Sciences specializes in advanced, precision-based cancer screening and diagnostic test portfolios designed to cover the entire continuum of cancer care.
Exact Sciences Corp., a leading advanced molecular diagnostics company renowned for revolutionizing cancer screening through non-invasive screening products like Cologuard, has its corporate headquarters located in Madison, Wisconsin.
Evaluating whether to invest in Exact Sciences Corporation (ticker EXAS) requires analyzing its competitive standing in advanced cancer screening and genomic diagnostics.
Yes, Exact Sciences Corporation is a legitimate, publicly recognized molecular diagnostics company based in Madison, Wisconsin.